Successful treatment of resistant SAPHO syndrome with anti-TNF therapy.
A 42-year-old Caucasian woman with SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) refractory to non-steroidal anti-inflammatory drugs, sulfasalzine, methotrexate, bisphosphonates and steroids was successfully treated with antitumour necrosis factor therapy (infliximab). This case was a diagnostic challenge leading to extensive investigations for infection and malignancy and delayed diagnosis for several years. We report the significant improvement in clinical, radiological and laboratory markers of disease activity on infliximab and the steroid sparing effect of such therapy.
Department of Rheumatology,  Aberdeen Royal Infirmary, Aberdeen,  UK.
Shayma Lamya
SL
Hampton
Hazem
H
Youssef
D020083:Acquired Hyperostosis Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D000069285:Infliximab; D011239:Prednisolone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D000069285:Infliximab